BIONXT SOLUTIONS INC.

BIONXT SOLUTIONS INC. Share · CA0909741062 · A3D1K3 (XCNQ) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BIONXT SOLUTIONS INC.
No Price
Closing Price XCNQ 01.05.2026: 0,50 CAD
01.05.2026 14:22
Current Prices from BIONXT SOLUTIONS INC.
ExchangeTickerCurrencyLast TradePriceDaily Change
XCNQ: CSE LISTED
CSE LISTED
BNXT.CN
CAD
01.05.2026 14:22
0,50 CAD
0,05 CAD
+11,11 %
XDUS: Düsseldorf
Düsseldorf
BNSIRS62.DUSB
EUR
30.04.2026 06:11
0,29 EUR
-
XHAM: Hamburg
Hamburg
BNSIRS62.HAMB
EUR
30.04.2026 06:06
0,30 EUR
-
XDQU: Quotrix
Quotrix
BNSIRS62.DUSD
EUR
30.04.2026 05:27
0,31 EUR
-
Share Float & Liquidity
Free Float 94,03 %
Shares Float 114,53 M
Shares Outstanding 121,81 M
Company Profile for BIONXT SOLUTIONS INC. Share
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Company Data

Name BIONXT SOLUTIONS INC.
Company BioNxt Solutions Inc.
Website https://xphyto.com
Primary Exchange XCNQ XETRA
WKN A3D1K3
ISIN CA0909741062
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Hugh A. D. Rogers
Market Capitalization 55 Mio
Country Canada
Currency EUR
Employees 0,0 T
Address 1820 Fir Street, V6J 3B1 Vancouver
IPO Date 2019-08-06

Ticker Symbols

Name Symbol
CSE LISTED BNXT.CN
Düsseldorf BNSIRS62.DUSB
Frankfurt BXT.F
Hamburg BNSIRS62.HAMB
Quotrix BNSIRS62.DUSD
XETRA BXT.DE
More Shares
Investors who hold BIONXT SOLUTIONS INC. also have the following shares in their portfolio:
Mangoceuticals, Inc. - Common Stock
Mangoceuticals, Inc. - Common Stock Share
SPDR PORTFOLIO DEVELOPED WORLD EX-US ETF
SPDR PORTFOLIO DEVELOPED WORLD EX-US ETF ETF